Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Karen Sorensen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 29
Vitrolife AB (Publ) Approves Dividend for the Financial Year 2024 Vitrolife AB (publ) at its AGM held on April 29, 2025, approved dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day. Announcement • Apr 10
Vitrolife AB (publ) Announces CFO Changes Vitrolife AB (publ) announced that Pär Ihrskog has been appointed CFO of the Vitrolife Group effective 10 October 2025. Pär currently serves as CFO at Bufab Group and brings a wealth of experience to the company, having also served as Group CFO/CIO at Embellence Group. He spent the majority of his career working in finance roles, of increasing seniority in SKF, also living and working in several countries, including the U.S. and China. Pär holds a master’s degree in business administration. Helena Wennerström will remain as acting CFO until Pär takes office. Announcement • Mar 31
Vitrolife AB (Publ) Appoints Rickard Ericsson as Svp Innovation Vitrolife AB (publ) announced that Rickard Ericsson, formerly SVP Consumables and SVP Sales & Marketing, has been appointed SVP Innovation, effective immediately. With over ten years at the company, Rickard brings a deep understanding of the reproductive health market. In this new role, he will oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management, and Market Access. The Executive Management Team (EMT) now consists of: CEO: Bronwyn Brophy O'Connor Acting CFO: Helena Wennerström, COO: Ermanno Sironi, SVP Innovation: Rickard Ericsson, SVP Sales & Marketing: Olivia Natens, CHRO: Jessica Jonasson. Announcement • Feb 21
The Vitrolife Group Appoints Ermanno Sironi as Chief Operating Officer The Vitrolife Group appointed Ermanno Sironi as Chief Operating Officer effective immediately. The COO will oversee the three business areas, Consumables, Technologies and Genetics as well as the IT organisation. The appointment supports continued execution of the corporate strategy to drive operational excellence, implementing a scalable operating model, optimising processes to realise synergies and leveraging digitalisation to increase productivity. Ermanno Sironi is a tenured MedTech executive with over 30 years' experience working in Operations, Finance and Business Development in global companies. Over the past year, he has served as a strategic advisor on operational excellence and business transformation to the Vitrolife Group's executive management team. Announcement • Jan 31
Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025 Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025. Location: gothenburg, Sweden Announcement • Jan 30
Vitrolife AB (Publ) Proposes Dividend The Board of Vitrolife AB (publ) proposed to the Annual General Meeting a dividend of SEK 149 (135) million, corresponding to SEK 1.10 (1.00) per share. Announcement • Dec 03
Vitrolife AB (Publ) Announces Chief Financial Officer Changes Vitrolife AB (publ) announced that Patrik Tolf will be stepping down as Chief Financial Officer due to personal reasons. Helena Wennerström will assume the role of acting CFO. Helena has extensive experience in finance and business management, including having served as CFO at ViaCon Group AB and EVP & CFO at Bulten AB. Helena Wennerström will immediately assume the role of acting CFO and Patrik will be here to support her during a transition period. The recruitment of a permanent CFO is being initiated. Announcement • Nov 16
Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025 Vitrolife AB (publ) announced that they will report fiscal year 2024 final results on Mar 27, 2025 Announcement • Oct 27
Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026 Vitrolife AB (publ) announced that they will report Q4, 2025 results on Jan 29, 2026 Announcement • Oct 04
Vitrolife AB (Publ) Announces Election Committee Appointments Vitrolife AB (publ) announced the following people have been appointed as members of the election committee for Vitrolife AB for the Annual General Meeting in 2025: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Patricia Hedelius, appointed by AMF Fonder & Pension; Jón Sigurdsson, Chairman of the Board. The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife AB on April 25, 2024. Announcement • May 23
Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V. Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.Vitrolife AB (publ) (OM:VITR) completed the acquisition of Stb Zorg B.V. on May 22, 2024. In 2023, Stb Zorg B.V. had revenues of €1.5 million. Board Change • May 04
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Karen Soerensen was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • May 03
Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million. Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash. Announcement • Apr 27
Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023 Vitrolife AB (publ) at the Annual General Meeting held on 25 April 2024, approved dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the record day. Buy Or Sell Opportunity • Apr 20
Now 21% undervalued Over the last 90 days, the stock has risen 3.7% to kr182. The fair value is estimated to be kr231, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Apr 18
First quarter 2024 earnings released: EPS: kr0.85 (vs kr0.74 in 1Q 2023) First quarter 2024 results: EPS: kr0.85 (up from kr0.74 in 1Q 2023). Revenue: kr841.0m (down 1.5% from 1Q 2023). Net income: kr115.0m (up 15% from 1Q 2023). Profit margin: 14% (up from 12% in 1Q 2023). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance. Board Change • Apr 18
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Karen Soerensen was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Mar 18
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Karen Sorensen was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 06
Full year 2023 earnings released: kr28.44 loss per share (vs kr2.91 profit in FY 2022) Full year 2023 results: kr28.44 loss per share (down from kr2.91 profit in FY 2022). Revenue: kr3.51b (up 8.6% from FY 2022). Net loss: kr3.85b (down kr4.25b from profit in FY 2022). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Board Change • Feb 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Karen Sorensen was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Feb 02
Vitrolife AB (publ) Proposes Dividend The board of Vitrolife AB (publ) to propose to the Annual General Meeting a dividend of SEK 135 (SEK 115 million) million, corresponding to SEK 1.00 (SEK 0.85) per share. The proposed dividend is based on exclusion of the non-cash impairment charge. 
